BLCO - Bausch + Lomb drops amid comments at JPMorgan Healthcare Conference
2024-01-08 16:17:29 ET
More on Bausch + Lomb
- Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
- Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript
- Bausch + Lomb wins FDA nod for eye surgery product
- Bausch + Lomb Non-GAAP EPS of $0.22 beats by $0.03, revenue of $1B beats by $9.86M
- Seeking Alpha’s Quant Rating on Bausch + Lomb
For further details see:
Bausch + Lomb drops amid comments at JPMorgan Healthcare Conference